Validation of Treg-based Therapy for Autoimmune Diseases

Treg validation is a key step in the development of cell therapy. To address the specific needs of our customers, Creative Biolabs has launched a special service in the validation of regulatory T cell (Treg)-based therapy for autoimmune diseases. We support Treg-based therapy development projects by providing high-quality Treg validation services, which leads to a better understanding of their properties and thereby their suitability for cell therapy. The tools developed in our lab are directly applicable to research in basic research and pharmaceutical industry.

T Regulatory Cell (Tregs) and Autoimmune Diseases

Treatment options for autoimmunity can involve the use of chemical and biological agents that suppress inflammation. While these treatment options for patients have shown to be beneficial in autoimmunity, they can result in patients being vulnerable to opportunistic infections. As an important inhibitory immune cell subset in vivo, Treg cells have shown great potential in the immunotherapy of various diseases, including autoimmune diseases.

Fig.1 Regulatory T cell-mediated mechanisms of suppression.¹

• Systemic lupus erythematosus (SLE)

Systemic lupus erythematosus (SLE) is a complex disease involving aberrant innate and adaptive immune responses. With increasing evidence for a key contribution of Treg cells in SLE, especially during disease flares, Treg-based therapy has been a hot spot in the treatment of SLE. Adoptive cell therapy (ACT) of ex vivo expanded Treg cells in autoantibody-positive diseased mice delayed the onset of renal complications and prolonged survival. A pilot study of 37 patients with SLE treated with a 5-day course of low-dose interleukin-2 (IL-2) showed clinical efficacy with increased Treg cell numbers and decreased SLE disease activity index scores.

• Autoimmune hepatitis (AIH)

Autoimmune hepatitis (AIH) is diagnosed based on an increase in liver enzyme levels in the presence of autoantibodies and immune cell infiltration in the liver. Scientists showed decreased Treg cell numbers in peripheral blood of 41 AIH patients compared with control subjects. It has been reported that liver tissue normally has very low concentrations of IL-2, and thus generally, it is not supportive of Treg cells' survival and function. Higher frequencies of intrahepatic Treg cells correlate with better response to therapy.

Custom Services of Treg-based Therapy Validation

A sufficient number of Treg cells is the foundation of immunotherapy; more importantly, the stability and activity of Treg cells are directly associated with the effectiveness of treatment. Our Treg cells validation services include but are not limited to: systematically examined the absolute count, stability, activity, and inhibitory function of Treg cells and possible changes in Treg cell function in the presence of cytokines that can stimulate inflammatory environments in vivo.

If you need customized services, you can refer to the following points to put forward your needs.

To better solve the problems in Treg-based therapy, Creative Biolabs not only provides customized Treg validation services, but also builds a communication platform for consultation on project issues. In terms of validation of Treg-based therapy for autoimmune diseases, any problem you encounter in your project will have a reasonable solution. Don't worry about projects anymore, contact us.

Reference

1. Kumagai-Takei, Naoko, et al. "The effects of asbestos fibers on human T cells." International Journal of Molecular Sciences 21.19 (2020): 6987. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only | Not For Clinical Use